Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Zanzalintinib

ZANACC

Exelixis · Phase 2 · Not yet recruiting · Enrollment 51

NCT07682675

Catalyst Primary completion. 04.2029. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmReported safety

A count stays a count. This page does not turn a count into a percent.